Evaxion Biotech As Stock Performance
| EVAX Stock | USD 3.31 0.09 2.65% |
The firm shows a Beta (market volatility) of 0.62, which means possible diversification benefits within a given portfolio. As returns on the market increase, Evaxion Biotech's returns are expected to increase less than the market. However, during the bear market, the loss of holding Evaxion Biotech is expected to be smaller as well. At this point, Evaxion Biotech AS has a negative expected return of -0.64%. Please make sure to confirm Evaxion Biotech's information ratio, as well as the relationship between the potential upside and rate of daily change , to decide if Evaxion Biotech AS performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Evaxion Biotech AS has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in March 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return (2.65) | Five Day Return 12.2 | Year To Date Return (29.72) | Ten Year Return (99.33) | All Time Return (99.33) |
Last Split Factor 1:5 | Last Split Date 2025-01-14 |
1 | How to build a dashboard for Evaxion Biotech A S Depositary Receipt stock - Watch List Verified Technical Trade Signals - newser.com | 11/14/2025 |
2 | Is Evaxion Biotech A S Depositary Receipt stock attractive for hedge funds - Volume Spike Weekly Watchlist for Hot Stocks - newser.com | 11/19/2025 |
3 | Evaxion Biotech Increases Share Capital Following Warrant Exercise - MSN | 11/21/2025 |
4 | Evaxion Biotech stock rises on promising AML vaccine data By Investing.com - Investing.com Nigeria | 12/08/2025 |
5 | Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2 | 12/19/2025 |
6 | Evaxion to present 2026 company milestones at Biotech Showcase conference in San Francisco next week | 01/07/2026 |
7 | Evaxion expands AI-Immunology platform into autoimmune diseases | 01/13/2026 |
8 | Evaxion AS Sponsored ADR Short Interest Down 21.9 percent in January | 02/04/2026 |
| Begin Period Cash Flow | 5.6 M | |
| Total Cashflows From Investing Activities | -3000.00 |
Evaxion Biotech Relative Risk vs. Return Landscape
If you would invest 546.00 in Evaxion Biotech AS on November 14, 2025 and sell it today you would lose (215.00) from holding Evaxion Biotech AS or give up 39.38% of portfolio value over 90 days. Evaxion Biotech AS is currently does not generate positive expected returns and assumes 6.17% risk (volatility on return distribution) over the 90 days horizon. In different words, 55% of stocks are less volatile than Evaxion, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Evaxion Biotech Target Price Odds to finish over Current Price
The tendency of Evaxion Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 3.31 | 90 days | 3.31 | over 95.46 |
Based on a normal probability distribution, the odds of Evaxion Biotech to move above the current price in 90 days from now is over 95.46 (This Evaxion Biotech AS probability density function shows the probability of Evaxion Stock to fall within a particular range of prices over 90 days) .
Evaxion Biotech Price Density |
| Price |
Predictive Modules for Evaxion Biotech
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Evaxion Biotech AS. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Evaxion Biotech Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Evaxion Biotech is not an exception. The market had few large corrections towards the Evaxion Biotech's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Evaxion Biotech AS, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Evaxion Biotech within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.85 | |
β | Beta against Dow Jones | 0.62 | |
σ | Overall volatility | 0.97 | |
Ir | Information ratio | -0.15 |
Evaxion Biotech Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Evaxion Biotech for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Evaxion Biotech AS can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Evaxion Biotech AS generated a negative expected return over the last 90 days | |
| Evaxion Biotech AS has high historical volatility and very poor performance | |
| Evaxion Biotech AS has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 3.34 M. Net Loss for the year was (10.57 M) with profit before overhead, payroll, taxes, and interest of 7.65 M. | |
| Evaxion Biotech AS currently holds about 25.25 M in cash with (12.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.06. | |
| Evaxion Biotech AS has a poor financial position based on the latest SEC disclosures | |
| Roughly 18.0% of the company shares are held by company insiders | |
| Latest headline from thelincolnianonline.com: Evaxion AS Sponsored ADR Short Interest Down 21.9 percent in January |
Evaxion Biotech Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Evaxion Stock often depends not only on the future outlook of the current and potential Evaxion Biotech's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Evaxion Biotech's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 1.1 M | |
| Cash And Short Term Investments | 5.1 M |
Evaxion Biotech Fundamentals Growth
Evaxion Stock prices reflect investors' perceptions of the future prospects and financial health of Evaxion Biotech, and Evaxion Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Evaxion Stock performance.
| Return On Equity | -0.65 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | (0.71) % | ||||
| Operating Margin | 0.40 % | ||||
| Current Valuation | 25.23 M | ||||
| Shares Outstanding | 8.34 M | ||||
| Price To Book | 4.81 X | ||||
| Price To Sales | 3.71 X | ||||
| Revenue | 3.34 M | ||||
| Gross Profit | 7.65 M | ||||
| EBITDA | (9.79 M) | ||||
| Net Income | (10.57 M) | ||||
| Cash And Equivalents | 25.25 M | ||||
| Cash Per Share | 1.06 X | ||||
| Total Debt | 10.1 M | ||||
| Debt To Equity | 0.48 % | ||||
| Current Ratio | 6.47 X | ||||
| Book Value Per Share | 2.61 X | ||||
| Cash Flow From Operations | (12.94 M) | ||||
| Earnings Per Share | (4.00) X | ||||
| Market Capitalization | 28.36 M | ||||
| Total Asset | 12.48 M | ||||
| Retained Earnings | (118.54 M) | ||||
| Working Capital | 4.4 M | ||||
About Evaxion Biotech Performance
Evaluating Evaxion Biotech's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Evaxion Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Evaxion Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -6.1 K | -6.4 K | |
| Return On Tangible Assets | (0.97) | (1.02) | |
| Return On Capital Employed | (2.09) | (1.98) | |
| Return On Assets | (0.97) | (1.02) | |
| Return On Equity | 5.76 | 6.04 |
Things to note about Evaxion Biotech AS performance evaluation
Checking the ongoing alerts about Evaxion Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Evaxion Biotech AS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Evaxion Biotech AS generated a negative expected return over the last 90 days | |
| Evaxion Biotech AS has high historical volatility and very poor performance | |
| Evaxion Biotech AS has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 3.34 M. Net Loss for the year was (10.57 M) with profit before overhead, payroll, taxes, and interest of 7.65 M. | |
| Evaxion Biotech AS currently holds about 25.25 M in cash with (12.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.06. | |
| Evaxion Biotech AS has a poor financial position based on the latest SEC disclosures | |
| Roughly 18.0% of the company shares are held by company insiders | |
| Latest headline from thelincolnianonline.com: Evaxion AS Sponsored ADR Short Interest Down 21.9 percent in January |
- Analyzing Evaxion Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Evaxion Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Evaxion Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Evaxion Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Evaxion Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Evaxion Biotech's stock. These opinions can provide insight into Evaxion Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Evaxion Stock Analysis
When running Evaxion Biotech's price analysis, check to measure Evaxion Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evaxion Biotech is operating at the current time. Most of Evaxion Biotech's value examination focuses on studying past and present price action to predict the probability of Evaxion Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evaxion Biotech's price. Additionally, you may evaluate how the addition of Evaxion Biotech to your portfolios can decrease your overall portfolio volatility.